Published in

MDPI, Toxins, 6(14), p. 383, 2022

DOI: 10.3390/toxins14060383

Links

Tools

Export citation

Search in Google Scholar

Treatment of Depression with Botulinum Toxin

Journal article published in 2022 by Marc Axel Wollmer, Michelle Magid, Tillmann H. C. Kruger ORCID, Eric Finzi
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Injection of botulinum toxin (BoNT) into the glabellar region of the face is a novel therapeutic approach in the treatment of depression. This treatment method has several advantages, including few side effects and a long-lasting, depot-like effect. Here we review the clinical and experimental evidence for the antidepressant effect of BoNT injections as well as the theoretical background and possible mechanisms of action. Moreover, we provide practical instructions for the safe and effective application of BoNT in the treatment of depression. Finally, we describe the current status of the clinical development of BoNT as an antidepressant and give an outlook on its potential future role in the management of mental disorders.